Joel David Mayersohn's Ownership and Stock Options in Citius Oncology, Inc.

Joel David Mayersohn, a director of Citius Oncology, Inc., reported ownership changes and stock options in the company. On July 28, 2025, Mayersohn acquired 21,228 shares of common stock through a distribution in kind from 10XYZ Holdings, the sponsor of TenX Keane Acquisition, the legacy entity of Citius Oncology. Additionally, Mayersohn holds 250,000 stock options granted on December 12, 2024, which will fully vest on the one-year anniversary of the grant date, provided he continues to serve the company. The options have an exercise price of $1.07 and expire on December 12, 2034. This filing highlights Mayersohn's continued involvement and financial interest in Citius Oncology.